{"id":"c-kad-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Limited public information is available on C-KAD's specific molecular mechanism. As an ophthalmic solution in early-stage development, it is likely designed to treat an eye condition through topical ocular delivery, but the exact target, drug class, and mechanism of action require access to proprietary clinical trial data or company disclosures.","oneSentence":"C-KAD Ophthalmic Solution is an investigational ocular therapeutic in phase 2 development by Chakshu Research, Inc., with mechanism details not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:25:22.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication(s) under investigation in phase 2 (specific indication not publicly available)"}]},"trialDetails":[{"nctId":"NCT06365762","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract","status":"COMPLETED","sponsor":"Livionex Inc.","startDate":"2006-01-01","conditions":"Age Related Cataracts","enrollment":111},{"nctId":"NCT00825396","phase":"NA","title":"An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension","status":"COMPLETED","sponsor":"Chakshu Research, Inc.","startDate":"2007-04","conditions":"Ocular Hypertension","enrollment":12},{"nctId":"NCT00825942","phase":"PHASE2","title":"An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis","status":"UNKNOWN","sponsor":"Chakshu Research, Inc.","startDate":"2008-07","conditions":"Asteroid Hyalosis","enrollment":20},{"nctId":"NCT00825721","phase":"PHASE2","title":"Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract","status":"UNKNOWN","sponsor":"Chakshu Research, Inc.","startDate":"2007-11","conditions":"Nuclear Cataract","enrollment":81},{"nctId":"NCT00793091","phase":"PHASE2","title":"Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract","status":"UNKNOWN","sponsor":"Chakshu Research, Inc.","startDate":"2008-11","conditions":"Cataract","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"C-KAD Ophthalmic Solution","genericName":"C-KAD Ophthalmic Solution","companyName":"Chakshu Research, Inc.","companyId":"chakshu-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C-KAD Ophthalmic Solution is an investigational ocular therapeutic in phase 2 development by Chakshu Research, Inc., with mechanism details not publicly disclosed. Used for Indication(s) under investigation in phase 2 (specific indication not publicly available).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}